Focusing on Asthma and Chronic Obstructive Pulmonary Disease with COVID-19.


Journal

Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410

Informations de publication

Date de publication:
31 10 2021
Historique:
received: 01 01 2021
accepted: 13 06 2021
entrez: 15 11 2021
pubmed: 16 11 2021
medline: 25 11 2021
Statut: epublish

Résumé

We aimed to evaluate clinical and laboratory findings of hospitalized asthma and chronic obstructive pulmonary disease (COPD) patients with COVID-19 and demonstrate that they have different symptoms and/or laboratory results and outcomes than COVID-19 patients with comorbidity (CoV-com) and without comorbidity (CoV-alone). The data of the demographic, clinical, laboratory findings of hospitalized CoV-alone, asthma, COPD patients with COVID-19 (CoV-asthma, CoV-COPD, respectively), and CoV-com were analyzed. Out of 1082 patients hospitalized for COVID-19, 585 (54.1%) had CoV-alone, 40 (3.7%) had CoV-asthma, 46 (4.3%) had CoV-COPD and 411 (38%) had CoV-com. Cough, shortness of breath, fever and weakness were the most common four symptoms seen in all COVID-19 patients. Shortness of breath, myalgia, headache symptoms were more common in CoV-asthma than the other groups (p < 0.001, p < 0.01, p < 0.05 respectively). Sputum was more common in CoV-COPD than other groups (p < 0.01). COPD group most frequently had increased values, different from the other groups with CRP>5ng/mL in 91.3%, D-dimer > 0.05mg/dL in 89.1%, troponin > 0.014micg/L in %63.9, INR>1.15 in 52.2%, CK-MB>25U/L in 48.5%, PT>14s in 40.9% of patients (p < 0.05, p < 0.001, p < 0.001, p < 0.001, p < 0.05, p < 0.001, respectively). NT-ProBNP was found to have the highest AUC value and the best differentiating parameter for CoV-asthma from CoV-alone. Typical CT findings were present in 44.4% of CoV-alone, 57.5% of CoV-asthma, 28.3% of CoV-COPD and 38.9% of CoV-com groups. CoV-COPD and CoV-com patients died more frequently than other groups (17.8%, 18.5%). CoV-asthma and CoV-COPD patients might have different symptoms and laboratory parameters than other COVID-19 patients which can guide the physicians.

Identifiants

pubmed: 34780364
doi: 10.3855/jidc.14611
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1415-1425

Informations de copyright

Copyright (c) 2021 Bilun Gemicioglu, Hafize Uzun, Sermin Borekci, Ridvan Karaali, Sebuh Kurugoglu, Pınar Atukeren, Sabri Sirolu, Sinem Durmus, Ahmet Dirican, Mert Ahmet Kuskucu, Fehmi Tabak.

Déclaration de conflit d'intérêts

No Conflict of Interest is declared

Auteurs

Bilun Gemicioglu (B)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Pulmonary Diseases, Istanbul, Turkey. bgemici@istanbul.edu.tr.

Hafize Uzun (H)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey.

Sermin Borekci (S)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Pulmonary Diseases, Istanbul, Turkey.

Ridvan Karaali (R)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.

Sebuh Kurugoglu (S)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Radiology, Istanbul, Turkey.

Pınar Atukeren (P)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey.

Sabri Sirolu (S)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Radiology, Istanbul, Turkey.

Sinem Durmus (S)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey.

Ahmet Dirican (A)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Biostatistic, Istanbul, Turkey.

Mert Ahmet Kuskucu (MA)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Microbiology, Istanbul, Turkey.

Fehmi Tabak (F)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH